
Kura Oncology Investor Relations Material
Latest events

Status Update
Kura Oncology
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Kura Oncology Inc
Access all reports
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company that develops medicines for the treatment of cancer in the United States. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications.
Key slides for Kura Oncology Inc


Q3 2024
Kura Oncology Inc


Status Update
Kura Oncology Inc
Latest articles
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
Ticker symbol
KURA
Country
🇺🇸 United States